Page 168 - Haematologica June

J. Celay et al.
AB
C
D
E
F
G
Figure 5. Therapeutic effect of the linear and the macrocyclic p17AE2 peptides on B-cell lymphomas. (A) Modelled 3D struc- tures of p17AE2, p17AE2-HT and p17AE2-Amide. Left, superpo- sition of conformation 1 of p17AE2 (< 5 Å, orange) and p17AE2- HT (green). Right, superposition of conformation 2 of p17AE2 (>10 Å, orange) and p17AE2-Amide (cyan). (B) Sensogram of surface plasmon resonance showing binding of p17AE2-Amide and p17AE2-HT to AE2 in a dose dependent manner. (C) Half- life and clearance of the different peptides in humans and mice. (D) Cell viability and apoptosis in UPN1, Jeko1, OCI-Ly1 cell lines after incubation with 50 μg/mL of truncated, p17AE2, p17AE2-HT and p17AE2-Amide peptides for 24 hours. (E) Similarly, the peptides reduced cell viability and promoted apoptosis of primary samples obtained from patients with B- cell lymphomas (n=10). (F, G) Representation of volumes of subcutaneous tumors in xenografted mice after intratumoral injection of 200 mg or 400 mg of truncated or p17AE2-HT pep- tides. *P<0.05; **P<0.01; ***P<0.001.
1070
haematologica | 2018; 103(6)